Engflag

Storvas CV

Quick links to important sections

Storvas CV

Storvas CV_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Storvas CV

Quick Facts

Property Description
Active ingredient Atorvastatin, Clopidogrel
Form Oral Capsule, Oral Tablet
Pharmacological class Statin (HMG-CoA Reductase Inhibitor) and Antiplatelet Agent (Thienopyridine)
Common use Dual management of high cholesterol and blood clot risk
Origin Synthetic

What Type of Medicine is Storvas CV?

Storvas CV is a synthetic fixed-dose combination product intended for oral administration, typically manufactured as a capsule or tablet. This formulation is distinctive because it integrates two separate active ingredients—Atorvastatin and Clopidogrel—into a single dosage unit, a strategy intended for improving patient adherence in chronic care. The Atorvastatin component is classified as an HMG-CoA Reductase Inhibitor, while the Clopidogrel component is an Antiplatelet Agent. The medicine is marketed by Sun Pharmaceutical Industries Ltd., a key feature distinguishing this specific product from other generic fixed-dose combinations.

The Dual Action Composition: Atorvastatin and Clopidogrel

The composition of Storvas CV utilizes Atorvastatin for its effect on blood lipids and Clopidogrel for its antithrombotic effect. The formulation provides the combination of a statin with an antiplatelet agent for cardiovascular protection. Atorvastatin’s role is to aid in lipid management, whereas Clopidogrel's function is to reduce the risk of platelet aggregation, thereby maintaining better blood flow. This dual approach is intended for high-risk patients who require management of both hypercholesterolemia and clotting risk.

General Purpose in Cardiovascular Risk Management

The overarching general therapeutic purpose of Storvas CV is to provide comprehensive, integrated protection against the underlying factors contributing to cardiovascular disease and recurrent atherosclerotic events. This fixed-dose combination serves as a component for long-term secondary prevention, reducing the likelihood of future vascular issues in high-risk adult patients. The combined class of agents is a recognized approach in managing these complex risks.

Regulatory References

  1. NIH Article on Atorvastatin and Clopidogrel Co-administration

What side effects are possible with Storvas CV?

Possible Side Effects and Safety Information

The official safety profile for Storvas CV, a fixed-dose combination of Atorvastatin and Clopidogrel, is determined by the distinct risks associated with each component. Regulatory documents classify adverse reactions by frequency and the body system affected, ensuring clarity regarding the known risks.

Key Adverse Reaction Categories

System-Organ Class Examples of Documented Effects
Musculoskeletal Arthralgia, Muscle Spasms, Myalgia, and the rare but serious Rhabdomyolysis (statin component).
Blood & Lymphatic System Bleeding events (e.g., epistaxis, gastrointestinal hemorrhage), and the rare Thrombotic Thrombocytopenic Purpura (TTP) (antiplatelet component).
Hepatobiliary Disorders Liver enzyme elevations, or the potential for Hepatic Failure in rare cases.
Gastrointestinal Common effects include Diarrhea, Dyspepsia, and Nausea.

Serious Adverse Reactions and Safety Constraints

The most serious reactions explicitly noted in regulatory documents include Rhabdomyolysis (severe muscle breakdown), Severe Bleeding, and TTP. The medicine is contraindicated in patients with active liver disease or unexplained persistent elevation of liver enzymes. Use is also strictly contraindicated during pregnancy and lactation and in individuals with active pathological bleeding.

Time-related patterns are also documented; for instance, Thrombotic Thrombocytopenic Purpura (TTP) has been reported following short exposure, and statin-associated cognitive impairment is typically noted as being reversible upon discontinuation. Safety classifications also note that older adults may have an increased risk of skeletal muscle effects associated with the statin component.

Overdose and Emergency Response

Any suspected overdose of Storvas CV requires immediate medical attention. The official regulatory profile for this combination medication is defined by the severe, distinct risks associated with its two active components, Atorvastatin and Clopidogrel. Emergency services should be contacted for life-threatening symptoms such as collapse or trouble breathing.

Overdose with the Clopidogrel component can lead to prolongation of bleeding time and subsequent severe or life-threatening hemorrhage. The most serious outcome listed is the potential for Thrombotic Thrombocytopenic Purpura (TTP), a rare but critical blood disorder. Overdose with the Atorvastatin component may result in rhabdomyolysis, a condition of severe muscle breakdown that carries the risk of acute renal failure. Elevated serum transaminases are also a documented laboratory finding associated with the statin component.

Management is strictly symptomatic and supportive, as no specific antidote is known for either component. Due to this constraint, continuous hospital monitoring is required to track vital signs, coagulation parameters, and liver function tests (LFTs). While supportive treatment is standard, specific interventions may include platelet transfusion for excessive bleeding or plasmapheresis if TTP is diagnosed. It is documented that hemodialysis is not expected to significantly enhance clearance of the Atorvastatin component due to high protein binding.

Therapeutic Uses of Storvas CV

What Storvas CV Treats: Main Uses and Benefits

Storvas CV (Atorvastatin/Clopidogrel) is a therapeutic combination commonly used for high-risk adult patients, supporting integrated, long-term defense against two key factors associated with heart and vascular disease: high cholesterol and the risk of clot formation. This class of medication is used as a therapeutic option in the management and prevention of cardiovascular disease.

The medication is applied across therapeutic domains involving elevated LDL cholesterol, triglycerides, and recurrent thrombotic risk. It is commonly applied in clinical contexts where major vascular events have already occurred, such as after a myocardial infarction or an ischemic stroke, and following procedures like coronary stenting. By managing the risk of pathological blood clot formation, the combination generally assists with long-term management aimed at lowering the risk that these disruptive events occur again.

“The dual approach is intended to assist in managing the progression of atherosclerotic risk and supports managing the risk of vascular damage over time.”

This integrated approach supports a broad defense by addressing these risk factors, contributing to the practical benefit of combined support that helps maintain a more stable, long-term health status, particularly for patients whose risk is compounded by co-existing factors like Type 2 diabetes or hypertension.

Quick Fact Support Provided
Support for Systemic Imbalance Assists with maintaining the overall lipid profile and managing vascular risk factors.
Clinical Scenarios Relevant when supportive long-term defense is appropriate following stenting or a previous heart attack.

Regulatory References

  1. NIH MedlinePlus overview of Atorvastatin

Eligibility and Restrictions for Use

Storvas CV is officially intended for use by adult patients (18 years and older). Regulatory labeling strictly defines specific populations who must not use the medicine, primarily due to the risks associated with its Atorvastatin and Clopidogrel components.

Populations for Whom Use is Contraindicated

Category Contraindication (Official Regulatory Wording)
Hemorrhagic Risk Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage).
Hepatic Function Active liver disease or unexplained persistent transaminase elevations.
Reproductive Status Pregnancy and breastfeeding/lactation.

Eligibility Restrictions

Use is not recommended for the pediatric population (under 18 years) as the safety and efficacy of the combination product are generally not established in this age group. Caution is required in adult patients with severe renal impairment, a history of liver disease, or predisposing factors for muscle damage, such as uncontrolled hypothyroidism. The elderly population is eligible for use but is identified as having a risk factor for myopathy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Contraindicated Combinations and Restrictions:

The regulatory profile for Storvas CV is structured by formal restrictions, including combinations that are officially contraindicated due to the documented risk of increased drug exposure. Co-administration with Cyclosporine, the antiviral combination Tipranavir plus Ritonavir, and Glecaprevir plus Pibrentasvir is strictly contraindicated because of the significant increase in Atorvastatin plasma concentrations. Gemfibrozil and Red Yeast Rice are also restricted for similar reasons.

Pharmacokinetic and Pharmacodynamic Alterations:

Interactions involving the CYP enzymes and drug transporters necessitate specific dose limitations. Strong CYP3A4 inhibitors (e.g., Clarithromycin, Itraconazole) require that the Atorvastatin dose must not exceed 20 mg daily. Co-administration with Omeprazole or Esomeprazole is cautioned against/avoided, as these agents reduce the antiplatelet activity of the Clopidogrel component by inhibiting the CYP2C19 enzyme. Furthermore, the concomitant use of NSAIDs, Warfarin, or other anticoagulants is documented to increase the risk of bleeding.

Specific Constraints and Population Notes:

A required timing rule exists for co-administration with Rifampin, which must be taken simultaneously with Atorvastatin to prevent a significant reduction in drug exposure. Ingestion of Grapefruit Juice can increase Atorvastatin plasma levels and is subject to consumption limits. Regulatory labels note that Atorvastatin plasma concentrations are markedly increased in patients with hepatic impairment, and the antiplatelet response to Clopidogrel is diminished in individuals identified as CYP2C19 poor metabolizers.

Mechanism of Action

The mechanism of action for Storvas CV is defined by the complementary and independent pharmacodynamic effects of its two active components, by modulating distinct molecular and cellular pathways relevant to the vascular process.

Atorvastatin acts through competitive inhibition of the enzyme HMG-CoA Reductase (HMGCR), the rate-limiting step in the liver's cholesterol synthesis pathway. This action lowers intracellular cholesterol, triggering the liver to increase surface expression of LDL receptors, which increases the clearance of atherogenic particles from the circulating blood.

Clopidogrel operates via its active metabolite, which achieves an irreversible antagonism of the P2Y12 purinergic receptor on platelets . By covalently binding to this receptor, Clopidogrel blocks the ADP-mediated signaling cascade essential for platelet activation and subsequent aggregation, achieving functional inhibition of the platelet aggregation cascade.

The two mechanisms complement each other: Atorvastatin’s mechanism also includes pleiotropic effects, modulating inflammatory mediator expression and affecting plaque integrity, which addresses the mechanisms underlying chronic vascular changes. Clopidogrel's mechanism results in durable functional inhibition of platelet aggregation, affecting the process of acute thrombus formation.

Dosage and Administration Information

How to Use Storvas CV

Storvas CV is a fixed-dose combination (FDC) medication of Atorvastatin and Clopidogrel, administered solely via the oral route. The medicine is designed for chronic, long-term use in accordance with clinical administration protocols. The regimen for maintenance therapy is a single tablet or capsule taken once daily.

Administration Scope

Parameter Instruction
Route of administration Oral (Tablet or Capsule)
Dosing schedule Adult maintenance: Atorvastatin component 10 mg to 80 mg combined with Clopidogrel 75 mg, once daily.
Timing in relation to meals Can be taken with or without food, and may be administered at any time of the day.
Preparation requirements The solid dosage form must be swallowed whole; it should not be crushed, broken, or chewed.
Age-group administration For children (10-17 years) with HeFH, the Atorvastatin component has a maximum recommended dose of 20 mg once daily.
Special procedural conditions Acute antiplatelet therapy often begins with a higher 300 mg Clopidogrel loading dose, administered separately, before initiating the FDC maintenance.

Use Protocol

Following the initial loading phase, the medication is integrated into a daily schedule. The established protocol typically involves evaluation and adjustment of the Atorvastatin component based on lipid levels. This dosage titration is usually performed as early as four weeks after starting therapy or making a dose change. This represents the documented administration approach for the FDC unit.

Recent Clinical Evidence

Research evidence / Overview of studies for Storvas CV

Evidence for Integrated Cardiovascular Risk Management

Research has explored the dual therapeutic approach (statin and antiplatelet agent) in the context of integrated risk management following a prior major atherosclerotic event, such as a heart attack (Myocardial Infarction) or an ischemic stroke. The primary evidence base consists of large-scale Randomized Controlled Trials (RCTs) and Systematic Reviews that examined the use of the two components together in high-risk adult populations. Research monitored physiological strain and systemic function axes in patients receiving the two components together.

Types of Studies Used to Support the Combination

This research relied heavily on RCTs, which involve comparing outcomes in groups of patients who are randomly assigned to receive one type of treatment or a comparator. These studies observed patient outcomes over defined time intervals. Additionally, Bioequivalence studies were applied in research examining the specific formulation of Storvas CV. Research explored whether the fixed-dose combination product delivers the two active components in the body similarly to when they are taken separately.

Research Focus: Outcomes and Patient Groups Studied

The studies included High-Risk Adult Patients who had experienced a major vascular event. The primary outcomes were major clinical events (such as cardiovascular death and non-fatal heart attack), as well as risk factor biomarkers. Trials monitored changes in Low-Density Lipoprotein Cholesterol (LDL-C) levels and platelet function. Studies report how these risk factors evolved in the observed populations over the study period, and evidence contributes to understanding patterns related to the combined therapeutic approach.

What Research Gaps and Uncertainties Exist

The evidence contributes to understanding patterns related to the combined therapeutic approach, but certainty remains low regarding certain aspects of its long-term study. The primary evidence covering clinical event findings was largely derived from research where the two components were taken separately. Therefore, information for event rates related to the fixed-dose combination is often drawn from research on the co-administered single components. Furthermore, sample sizes for some of the studies focusing specifically on the fixed-dose formulation were limited.

Key Studies & References

  1. An application to include fixed dose combinations in the WHO Model List of Essential Medicines for primary and secondary prevention
  2. Effectiveness of Single-Tablet Combination Therapy in Improving Adherence and Persistence and the Relation to Clinical and Economic Outcomes
  3. Secondary prevention therapies following percutaneous coronary intervention or acute coronary syndrome in patients with diabetes mellitus

Frequently Asked Questions (FAQ)

Common questions about Storvas CV (FAQ)

Q: Is Storvas CV a blood pressure medicine?

Official drug information defines Storvas CV as a fixed-dose combination of a lipid-lowering agent (Atorvastatin) and an antiplatelet agent (Clopidogrel). Its primary purpose is to manage high cholesterol and reduce the risk of cardiovascular events and is not generally listed for the treatment of high blood pressure.

Q: Is it normal to feel dizzy when starting Storvas CV?

Feeling dizzy, or dizziness, is documented in the official safety information for the Clopidogrel component, where it is listed as an uncommon side effect. Concerns about side effects can be discussed with a healthcare professional.

Q: What happens if I stop taking Storvas CV suddenly?

Regulatory guidance emphasizes that discontinuation of the antiplatelet component (Clopidogrel), especially after procedures like stent placement, may be associated with an increased risk of serious cardiovascular events. Any changes to the medication regimen are decisions that are determined in consultation with a prescribing healthcare provider.

Q: What is the difference between Storvas CV and other statin-based medicines?

Storvas CV is distinctive because it is a fixed-dose combination (FDC) that contains two active components: a statin (Atorvastatin) and an antiplatelet agent (Clopidogrel). Many other statin-based medicines contain only the statin or utilize different combination agents.

Q: Does Storvas CV require a prescription?

Yes, Storvas CV is classified by regulatory bodies as a prescription-only medicine and requires a valid prescription from an authorized healthcare provider to be dispensed.

Q: Is it possible to be allergic to Storvas CV?

Official information states that the medicine is contraindicated (should not be used) in patients with known hypersensitivity (an allergic reaction) to either Atorvastatin, Clopidogrel, or any of the inactive ingredients in the tablet or capsule.

Q: Can Storvas CV make me gain or lose weight?

Weight gain is specifically listed in the safety documentation as a common adverse reaction for the Atorvastatin component of the medicine.

Q: What should I do if I miss a dose of Storvas CV?

Regulatory guidance describes a specific protocol for managing a missed dose, typically advising on taking or skipping the dose based on the elapsed time. Patients should reference the specific guidance provided by their healthcare professional or medication packaging for the exact timing rules.

Q: Does Storvas CV interact with alcohol?

Official documents advise that the Atorvastatin component should be used with caution in patients who consume substantial quantities of alcohol. This is often noted because of the potential for the combination to be associated with liver-related effects.

Q: Why is it important to take Storvas CV at the same time each day?

Although the medicine may be administered at any time of the day, taking it at the same time daily helps to establish a consistent routine. This regular schedule helps the body maintain consistent drug levels over the course of the long-term treatment.

Q: Does Storvas CV affect blood sugar levels?

Official regulatory labels note that statins, like the Atorvastatin component, may be associated with increases in HbA1c and fasting blood glucose levels. This is a documented class effect, particularly observed in patient populations with existing risk factors for diabetes.

Q: Can Storvas CV cause problems with sleep?

Insomnia, or sleeplessness, is listed in the official safety documentation as a common side effect for the Atorvastatin component.

Q: What if I'm taking Storvas CV and need surgery?

The Clopidogrel component increases the risk of bleeding. Regulatory guidance states that if a patient needs elective surgery and the antiplatelet effect must be temporarily stopped, Clopidogrel is generally discontinued 7 days prior to the procedure, following the guidance of their specific healthcare provider.

Q: Does Storvas CV have an effect on energy levels?

Fatigue, or general tiredness, is noted in official safety documentation as a common adverse reaction related to the Atorvastatin component of the medicine.

Q: Is headache a common issue reported with Storvas CV?

Yes, headache is listed in regulatory safety documentation as a common adverse reaction for both the Atorvastatin and Clopidogrel components.

Q: Can Storvas CV affect vision or hearing?

Safety documentation indicates that visual disturbances and eye irritation are listed as uncommon side effects for the Clopidogrel component. Visual impairment, along with hearing loss and tinnitus (ringing in the ears), are also listed as uncommon side effects for the Atorvastatin component.

Q: Does Storvas CV thin the blood?

The Clopidogrel component is classified as an antiplatelet agent, which works by inhibiting platelet aggregation (предотвратяване на слепването на кръвните клетки). This mechanism is often referred to by patients as 'blood thinning,' as it helps prevent unwanted blood clots.

Q: What are the most commonly reported side effects of Storvas CV?

Based on clinical trial data, common adverse events (those occurring in 1% to 10% of patients) included nasopharyngitis (a cold or sore throat), arthralgia (joint pain), diarrhea, nausea, and dyspepsia (indigestion). The complete list of documented effects is available in the 'Side Effects' section of the official product information.

Q: How long does it typically take for Storvas CV to start working?

Official information indicates that the effects on 'bad cholesterol' (LDL-C) are typically first observed within 2 weeks, with maximum response achieved around 4 weeks. The antiplatelet effects, meanwhile, can be established within hours if a loading dose is given separately, or over several days with the standard maintenance dose.

Q: Does Storvas CV work for everyone who takes it?

Official regulatory documents note that the antiplatelet effect of Clopidogrel can be diminished in some individuals who have genetic differences that classify them as CYP2C19 poor metabolizers. This indicates that response to the medication may vary among individuals.

Q: Is Storvas CV considered a high-risk medication?

Regulatory agencies require that the medicine carry specific Boxed Warnings regarding the potential for serious adverse reactions. These include a risk of serious bleeding and rare but severe muscle breakdown (Rhabdomyolysis), which are conditions healthcare professionals must monitor for.

Q: What kind of monitoring is needed while taking Storvas CV?

Official labels advise that Liver Function Tests be performed before treatment begins and periodically thereafter. Evaluation of lipid levels is also routinely performed to guide potential dose adjustments for the Atorvastatin component.

Q: Is Storvas CV related to aspirin?

Both the Clopidogrel component and Aspirin are classified as agents that help prevent blood clots (antiplatelet agents). Although they work through different mechanisms in the body, they are sometimes used together in certain treatment protocols.

Q: Is there a generic version of Storvas CV available?

Yes, regulatory bodies have approved generic fixed-dose combination products containing the same active ingredients—Atorvastatin and Clopidogrel—available in various strengths.

How should Storvas CV be stored and disposed of?

Storage and Disposal of Storvas CV

Storvas CV (atorvastatin/clopidogrel) must be stored and handled according to regulatory specifications to ensure stability and safety.

Storage Requirements

  • Temperature: Store the medicine at controlled room temperature, typically 20 C to 25 C, and below 30 C. Do not freeze the product.
  • Protection: The product must be protected from light and moisture. Keep it in the original container or packaging.
  • Child Safety: It is mandatory to keep Storvas CV out of the sight and reach of children.
  • Stability: Do not use the medicine after the expiration date printed on the package.

Disposal Instructions

Unused or expired Storvas CV must be disposed of properly according to local regulations.

  • Prohibited Methods: Do not flush the medicine down the toilet or throw it into household waste.
  • Official Procedure: Use official guidelines, such as drug take-back programs or pharmacy collection points, for discarding the unused product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Storvas CV found in:

A-Z Index: